Hidekatsu Nakai, Takahiro Higashi, Tamaki Kakuwa, Noriomi Matsumura. Trends in gynecologic cancer in Japan: incidence from 1980 to 2019 and mortality from 1981 to 2021. International journal of clinical oncology. 2024
Shin Nishio, Kenta Murotani, Wataru Yamagami, Shiro Suzuki, Hidekatsu Nakai, Kazuyoshi Kato, Hideki Tokunaga, Hiroyuki Nomura, Yoshihito Yokoyama, Kazuhiro Takehara, et al. Pretreatment systemic inflammatory markers predict survival in endometrial cancer: A Japanese Gynecologic Oncology Group 2043 exploratory data analysis. Gynecologic Oncology. 2024. 181. 46-53
Hidekatsu Nakai, Noriomi Matsumura. Selection of maintenance therapy during first-line treatment of advanced ovarian cancer based on pharmacologic characteristics. Expert opinion on pharmacotherapy. 2023. 1-13
Masato Shono, Kosuke Murakami, Mamiko Ohta, Hidekatsu Nakai, Noriomi Matsumura. Interstitial lung disease caused by niraparib in ovarian cancer patient: a case report and literature review. Japanese journal of clinical oncology. 2023
竹島 信宏, 安岡 稔晃, 濱西 潤三, 長谷川 幸清, 松浦 基樹, 三浦 清徳, 長尾 昌二, 中井 英勝, 田中 尚武, 徳永 英樹, et al. プラチナ製剤感受性の日本人再発卵巣癌患者を対象としたニラパリブの第II相臨床試験の最終結果(The Final Results of a Phase 2 Study of Niraparib in Japanese Patients with Platinum-Sensitive Recurrent Ovarian Cancer). 日本婦人科腫瘍学会学術講演会プログラム・抄録集. 2022. 64回. 192-192
中村 俊昭, 田畑 務, 柳田 聡, 近藤 英司, 濱西 潤三, 原野 謙一, 長谷川 幸清, 平澤 猛, 堀 謙輔, 小宮山 慎一, et al. 前治療歴を有する高悪性度漿液性卵巣癌患者を対象としたニラパリブの国内第II相臨床試験の最終結果(The Final Results of a Japanese Phase 2 Study of Niraparib in Heavily Pretreated, HRd High-grade Serous Ovarian Cancer Patients). 日本婦人科腫瘍学会学術講演会プログラム・抄録集. 2022. 64回. 193-193